Compare Immunovant Inc. Common Stock (IMVT) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs MobilEye Global Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.41 (market cap $6.25B), while MobilEye Global Inc trades at $7.19 (market cap $6.00B). The key difference: Immunovant Inc. Common Stock and MobilEye Global Inc are close in size by market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and MobilEye Global Inc for 15 Days on average.
| IMVT | MBLY | |
|---|---|---|
Market Cap | $6.25B | $6.00B |
Volume | 1,755,411 | 7,007,849 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $15.42 |
52-Week Low | $17.03 | $6.56 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $5.35B | $4.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mobileye Global (MBLY) trades at $7.14, down 0.14% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $2.0B in 2026 but faces significant profitability challenges with a -201.49% net income margin. Analyst consensus is mixed with 57.7% buy ratings but a bearish technical outlook from indicators.
The stock presents a high-risk opportunity with substantial upside to the $10.83 consensus target but requires careful monitoring of profitability improvements. Key risks include persistent losses, competitive pressures in autonomous driving, and execution challenges in robotaxi expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
